ZI
ZIM.F Zimmer Biomet Holdings Inc
- Market cap
- EUR 18.2B
- P/E
- 28.3x
- P/B
- 1.59x
- ROE
- 6.6%
- Dividend yield
- 0.89%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ZIM.F undervalued?
Graham numberZIM.F trades 41.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zimmer Biomet Holdings Inc fundamental analysis
No fundamental analysis for Zimmer Biomet Holdings Inc yet.
Zimmer Biomet Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoraci…
Full company profileZimmer Biomet Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zimmer Biomet Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.68B | 7.82B | 7.93B | 7.98B | 7.02B | 7.84B | 6.94B | 7.39B | 7.68B | 8.23B | 8.44B |
| Gross Profit | 5.30B | 5.69B | 5.66B | 5.73B | 4.90B | 5.50B | 4.92B | 5.31B | 5.49B | 5.74B | 6.03B |
| Operating Income | 1.09B | 1.35B | 1.15B | 1.27B | 698M | 1.01B | 1.19B | 1.45B | 1.53B | 1.36B | 1.48B |
| EBITDA | - | 1.85B | 1.06B | 2.14B | 970M | 1.69B | 1.49B | 2.22B | 2.25B | 2.22B | 2.43B |
| Net Income | 306M | 1.81B | -379M | 1.13B | -139M | 402M | 231M | 1.02B | 904M | 705M | 837M |
| EPS | - | 8.95 | -1.86 | 5.49 | -0.67 | 1.92 | 1.11 | 4.98 | 4.54 | 3.61 | 4.40 |
| Balance Sheet | |||||||||||
| Total Assets | 26.7B | 26.0B | 24.1B | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 21.4B | 23.1B | 23.5B |
| Total Liabilities | 17.0B | 14.2B | 12.9B | 12.2B | 12.2B | 10.8B | 9.04B | 9.01B | 8.89B | 10.4B | 10.8B |
| Shareholders' Equity | 9.67B | 11.7B | 11.3B | 12.4B | 12.2B | 12.7B | 12.0B | 12.5B | 12.5B | 12.7B | 12.7B |
| Cash & Short-term Investments | 634M | 524M | 543M | 618M | 802M | 479M | 376M | 416M | 526M | 592M | 400M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.63B | 1.58B | 1.75B | 1.59B | 1.20B | 1.50B | 1.28B | 1.24B | 1.50B | 1.70B | 1.82B |
| Capital Expenditure | 185M | 493M | 439M | 523M | 371M | 417M | 446M | 378M | 357M | 277M | 390M |
| Free Cash Flow | - | 1.43B | 1.58B | 1.18B | 1.09B | 1.33B | 1.10B | 859M | 1.14B | 1.42B | 1.43B |
| Ratios | |||||||||||
| ROE | 3.2% | 15.5% | -3.4% | 9.1% | -1.1% | 3.2% | 1.9% | 8.2% | 7.2% | 5.6% | 6.6% |
| ROA | 1.1% | 7.0% | -1.6% | 4.6% | -0.6% | 1.7% | 1.1% | 4.8% | 4.2% | 3.1% | 3.6% |
| Net Profit Margin | 4.0% | 23.2% | -4.8% | 14.2% | -2.0% | 5.1% | 3.3% | 13.8% | 11.8% | 8.6% | 9.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zimmer Biomet Holdings Inc dividends
- Dividend yield
- 0.89%
- Forward dividend
- 0.86 EUR
- Payout ratio
- 27.0%
- Ex-dividend date
- Sep 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 190M | 0.97 | 27.0% |
| 2024 | USD 196M | 0.98 | 21.7% |
| 2023 | USD 201M | 0.98 | 19.6% |
| 2022 | USD 201M | 0.96 | 86.9% |
| 2021 | USD 200M | 0.96 | 49.8% |
| 2020 | USD 199M | 0.96 | - |
| 2019 | USD 197M | 0.95 | 17.4% |
| 2018 | USD 195M | 0.96 | - |
| 2017 | USD 194M | 0.96 | 10.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Zimmer Biomet Holdings Inc
- Insiders 0.16%
- Institutions 99.84%
- Public & others 0.00%
- Shares outstanding 189M
- Free float 189M
Zimmer Biomet Holdings Inc company profile
- Company name
- Zimmer Biomet Holdings Inc
- Ticker
- ZIM.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17,000
- Fiscal year end
- December
- Address
- 345 East Main Street, Warsaw, IN, United States, 46580
- Phone
- 574 373 3333
- Website
- zimmerbiomet.com
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Zimmer Biomet Holdings Inc management
10- Mr. Ivan TornosPresident, CEO & Chairman of the Board · born 1975
- Mr. Wilfred van ZuilenGroup President of Europe, Middle East & Africa · born 1970
- Mr. JehanZeb NoorSenior VP, Chief Strategy, Business Development, Innovation & Transformation Officer · born 1982
- Mr. Paul A. StellatoInterim CFO, VP, Controller & Chief Accounting Officer · born 1975
- Mr. Shaun BraunSenior VP & Chief Information and Technology Officer
- Dr. Jonathan M. Vigdorchik M.D.Chief Science, Technology & Medical Affairs Officer
- Mr. David M. DeMartinoSenior Vice President of Investor Relations
- Mr. Chad F. Phipps J.D.Senior VP, Chief Legal & Corporate Affairs Officer and Secretary · born 1972
- Ms. Angela MainSenior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific
- Ms. Kristen CardilloSenior VP & Chief Communications Officer